Loss of short-term buyer interest sends GSK stock sliding

Traders Union
All News
Financial News
GSK drops 1.56% to GBX 1,898.50

Highlights

GSK has acquired Canadian biotech firm 35Pharma Inc., expanding its clinical-stage asset portfolio and enhancing R&D capabilities.
Initial clinical data for GSK's new cancer therapy Mo-rez show promising tumor reduction in advanced cancer patients.
Shares remain under sustained short- and medium-term selling pressure, with the price likely to consolidate in the GBX 1,860–1,940 range and further downside risk if support fails.

Pipeline expansion and trial results counter broad selling pressure

GSK completed its acquisition of the Canadian biopharmaceutical company 35Pharma Inc., incorporating additional clinical-stage assets into its pipeline and broadening its R&D capabilities. The company also reported encouraging preliminary results for its experimental cancer drug Mo-rez, with early data showing reduced tumor size in patients with advanced cancers. Both events are likely to influence the asset’s future positioning, though price action has remained under broader selling pressure.

Downward momentum intensifies as technicals signal oversold state

The GBX 1,898.50 level sits below the SMA-20 (GBX 2,083.00) and SMA-50 (GBX 2,081.46), while it remains above the SMA-200 (GBX 1,788.96). The Ichimoku Kijun at GBX 2,026.25 acts as immediate resistance. Momentum is weak, as shown by a negative MACD and low ADX on the daily chart. RSI (29.78), Stoch RSI (0.23), and CCI (–169.85) reflect oversold conditions, with BBP (–89.22) indicating seller dominance through most of the session. The Awesome Oscillator and session price action near today's low further support this assessment.

Sideways trading likely as breakout odds remain subdued

Over the next five trading days, GSK is expected to trade within a GBX 1,860 to GBX 1,940 volatility band relative to current levels, with sideways price action anticipated. The probability of a breakout to the upside remains low, while further declines may emerge if the GBX 1,860 support is breached. A sustained reversal would require a close above the immediate resistance at GBX 2,026.

Anton Kharitonov, expert at Traders Union, sees GSK’s improved pipeline from the 35Pharma acquisition and the early Mo-rez results as positives for long-term growth. However, he notes that technical momentum remains weak, with major moving averages acting as resistance and oscillators showing the stock in oversold territory. Base case remains sideways to lower unless GBX 2,026 is reclaimed. "As long as GSK trades below immediate resistance, I remain cautious and see no strong buy signals here."

Earlier, analysts noted that GSK was experiencing sustained technical weakness despite solid fundamentals, with a broadly neutral to bearish outlook dominating its near-term prospects. The current combination of continued selling pressure and oversold momentum, even as pipeline advances progress, underscores the importance of monitoring GBX 1,860 as a critical support level for potential downside risk.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.